GSK-Backed Ouro Launches With $120m For T-Cell Engagers In Autoimmune Diseases
Lead TCE, Licensed From Keymed, Targets BCMA
Ouro Medicines, founded by Monograph Capital and GSK and helmed by HI-Bio veterans, aims to reset the immune system in B-cell-mediated diseases with options that are not CAR-T therapies.
